Serotonin-related
32 combinations in this group
MAO — Monoamine oxidase
MAO — monoamine oxidase
An enzyme involved in breaking down serotonin.
Breakdown and reuptake are different processes.
Sources: MAO — monoamine oxidase
- OpenStax: Neurotransmitters Made from Amino Acids · Introduction to Behavioral Neuroscience, published 2024-11-13
Monoamine oxidase inhibition; MAO-A activity is particularly relevant to serotonin toxicity
Combinations with MAO
- DXM + Harmine, harmaline, Syrian rue, ayahuasca, harmala-containing changaPHI 8 to 9
Group assessment
This PHI covers the named group; its members do not have separate PHI ratings.
- DXM + Other reversible MAO-A inhibitorsPHI 8 to 9
Group assessment
This PHI covers the named group; its members do not have separate PHI ratings.
- DXM + Phenelzine, tranylcypromine, isocarboxazidPHI 9
Group assessment
This PHI covers the named group; its members do not have separate PHI ratings.
- DXM + Selegiline or rasagiline, when MAO-B selectivity is lostPHI 8 to 9
Group assessment
This PHI covers the named group; its members do not have separate PHI ratings.
SERT — Serotonin reuptake
SERT
A transporter protein involved in serotonin reuptake.
Inhibiting transport differs from acting on receptors.
Sources: SERT
- IUPHAR Pharmacology Education Project: Receptors · Live page accessed 2026-10-12; revision label unavailable
Serotonin reuptake inhibition
Combinations with SERT
- DXM + Clomipramine and other tricyclic antidepressants (TCAs)PHI 6 to 8
Group assessment
This PHI covers the named group; its members do not have separate PHI ratings.
- DXM + Fluoxetine, paroxetinePHI 7 to 8
Group assessment
This PHI covers the named group; its members do not have separate PHI ratings.
- DXM + Sertraline, escitalopram, citalopram, fluvoxaminePHI 6 to 7
Group assessment
This PHI covers the named group; its members do not have separate PHI ratings.
- DXM + Venlafaxine, desvenlafaxinePHI 6 to 7
Group assessment
This PHI covers the named group; its members do not have separate PHI ratings.
REL — Monoamine release
Neurotransmitter release
Movement of neurotransmitter molecules from a nerve ending into the space between cells.
During release a neurotransmitter leaves a nerve ending; during reuptake it returns into a cell.
Sources: Neurotransmitter release
- OpenStax: General Neurochemistry Principles · Introduction to Behavioral Neuroscience, published 2024-11-13
Monoamine release, with serotonergic contribution where indicated
Combinations with REL
- DXM + MDA, serotonergic cathinones, and other serotonergic releasersPHI 7 to 9
Group assessment
This PHI covers the named group; its members do not have separate PHI ratings.
- DXM + Amphetamine, dextroamphetaminePHI 5 to 7 ? uncertain contribution
Group assessment
This PHI covers the named group; its members do not have separate PHI ratings.
5HT-R — Serotonin receptors
Receptor
A protein that binds particular molecules and participates in a cell response.
Different receptors have different functions.
Sources: Receptor
- IUPHAR Pharmacology Education Project: Receptors · Live page accessed 2026-10-12; revision label unavailable
Serotonin receptor effects; does not mean the same mechanism as release or SERT inhibition
Combinations with 5HT-R
- DXM + NBOMe compounds, including 25I, 25B, 25CPHI 6 to 8
Group assessment
This PHI covers the named group; its members do not have separate PHI ratings.
- DXM + DOx compounds, including DOM, DOB, DOCPHI 4 to 6
Group assessment
This PHI covers the named group; its members do not have separate PHI ratings.
- DXM + LSD, psilocybin, psilocinPHI 1 to 3
Group assessment
This PHI covers the named group; its members do not have separate PHI ratings.
How these processes differ
Serotonin processes
Qualitative illustration: highlights do not measure concentration, effect strength or danger.
Release
Monoamine release, with serotonergic contribution where indicated
Reuptake
Serotonin reuptake inhibition
MAO metabolism
Monoamine oxidase inhibition; MAO-A activity is particularly relevant to serotonin toxicity
Receptor action
Serotonin receptor effects; does not mean the same mechanism as release or SERT inhibition
Reference view of the four processes. Choose an example to read its source explanation. Highlighting marks the selected process.
LSD / psilocybin / psilocin
MDMA
A controlled study involved 15 healthy men. They took MDMA by mouth, followed by DXM as a metabolic probe. DXM Cmax and AUC increased approximately tenfold, while DXO measures decreased [3].
The abstract reports CYP2D6 recovery after approximately 10 days and a recovery half-life of 46.6 hours. The full text estimates that half-life by fitting a monoexponential model to a urinary metabolic-ratio marker. At the 10-day observation, the Results and Discussion describe a remaining departure of the marker from baseline and limitations of the recovery models [3].
These findings describe pharmacokinetics and enzyme-probe measurements. The fold change can differ at other doses because of metabolic saturation and exposure-dependent inhibition. The study did not measure poisoning rates during combined recreational use or establish an individual safe waiting interval.
The authors note that the estimate appears to underestimate the time to recovery. They question the validity of a longer biphasic-model estimate because of variability in the data and insufficient data points over time [3].